Can regulation reduce risks associated with investing in early-stage firms? Using the passage of the European Orphan Drug Act (EU-ODA), we examine this question in the biopharmaceutical industry. We provide [...]
Artists have always loved to hate the art market. They want to sell their work, but only on their own terms. Unfortunately, they usually lack the means to explain what [...]
We build a model of firm-level innovation, productivity growth and reallocation featuring endogenous entry and exit. A new and central economic force is the selection between high- and low-type firms, [...]
The condominium structure, which facilitates ownership of units in multi-family buildings, was only introduced to the US during the 1960s. We ask whether the subsequent development of condominiums encouraged high-income [...]
The United States (‘US’) extended most copyright terms by 20 years in 1998, and has since exported that extension via ‘free trade’ agreements to countries including Australia and Canada. A [...]
What proportion of patent applications filed at the U.S. Patent and Trademark Office (USPTO) are eventually granted? Many experts have suggested that the USPTO approves nearly all applications, blaming this [...]
This Article explores how copyright law addressed the issue of innocent infringement in its early years. Part I discusses how copyright law, from its beginnings in England in 1709 and [...]
The support for scientific investigation in biomedicine depends in part on the adoption of new knowledge into medical practice. We investigate how a technological advance, in the form of a [...]
Suing actual infringers is passe in copyright law. In the digital environment, the real stakes lie in suing those who facilitate infringement by others. There is of course a good [...]
Free trade has contributed to a ‘great convergence’ of emerging market countries toward incomes in industrialised nations in recent decades. It is less clear whether free mobility of capital across [...]